Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism of Eravacycline Resistance in Clinical Enterococcus faecalis Isolates From China
Authors
Keywords
-
Journal
Frontiers in Microbiology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-05-25
DOI
10.3389/fmicb.2020.00916
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Eravacycline: A Novel Fluorocycline
- (2020) Sara Alosaimy et al. PHARMACOTHERAPY
- Eravacycline: A Review in Complicated Intra-Abdominal Infections
- (2019) Lesley J. Scott DRUGS
- The Enterococcus: a Model of Adaptability to Its Environment
- (2019) Mónica García-Solache et al. CLINICAL MICROBIOLOGY REVIEWS
- Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline
- (2019) Matthew W. McCarthy CLINICAL PHARMACOKINETICS
- Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans
- (2019) Tao He et al. Nature Microbiology
- Eravacycline, a newly approved fluorocycline
- (2019) Young Ran Lee et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Plasmid-encoded tet(X) genes that confer high-level tigecycline resistance in Escherichia coli
- (2019) Jian Sun et al. Nature Microbiology
- The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
- (2019) Shao-Huan Lan et al. Journal of Clinical Medicine
- Pathogenicity of Enterococci
- (2019) Elizabeth Fiore et al. Microbiology Spectrum
- Novel Plasmid-Mediated tet(X5) Gene Conferring Resistance to Tigecycline, Eravacycline, and Omadacycline in a Clinical Acinetobacter baumannii Isolate
- (2019) Liyuan Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Omadacycline Efficacy against Enterococcus faecalis Isolated in China: In Vitro Activity, Heteroresistance, and Resistance Mechanisms
- (2019) Zhiwei Lin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015
- (2018) George G. Zhanel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Combatting resistant enterococcal infections: a pharmacotherapy review
- (2018) Nicholas J Mercuro et al. EXPERT OPINION ON PHARMACOTHERAPY
- Overexpression of OqxAB and MacAB efflux pumps contributes to eravacycline resistance and heteroresistance in clinical isolates of Klebsiella pneumoniae
- (2018) Jin-xin Zheng et al. Emerging Microbes & Infections
- Eravacycline activity against clinical S. aureus isolates from China: in vitro activity, MLST profiles and heteroresistance
- (2018) Fan Zhang et al. BMC MICROBIOLOGY
- Molecular basis for the emergence of a new hospital endemic tigecycline-resistant Enterococcus faecalis ST103 lineage
- (2018) Andrei Nicoli Gebieluca Dabul et al. INFECTION GENETICS AND EVOLUTION
- Impact on Public Health of the Spread of High-Level Resistance to Gentamicin and Vancomycin in Enterococci
- (2018) Mónica Sparo et al. Frontiers in Microbiology
- Multidrug-Resistant Enterococcal Infections: New Compounds, Novel Antimicrobial Therapies?
- (2017) Roel M. van Harten et al. TRENDS IN MICROBIOLOGY
- Characteristics of and Virulence Factors Associated with Biofilm Formation in Clinical Enterococcus faecalis Isolates in China
- (2017) Jin-Xin Zheng et al. Frontiers in Microbiology
- Antibacterial Efficacy of EravacyclineIn Vivoagainst Gram-Positive and Gram-Negative Organisms
- (2016) Marguerite L. Monogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
- (2016) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
- (2016) George G. Zhanel et al. DRUGS
- Tetracycline Antibiotics and Resistance
- (2016) Trudy H. Grossman Cold Spring Harbor Perspectives in Medicine
- The Ribosomal S10 Protein Is a General Target for Decreased Tigecycline Susceptibility
- (2015) Kathryn Beabout et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in Enterococcus faecium
- (2015) Marc Niebel et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Genomic Analysis of Reduced Susceptibility to Tigecycline in Enterococcus faecium
- (2014) Vincent Cattoir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City
- (2014) Marie Abdallah et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tetracycline antibiotics and resistance mechanisms
- (2014) Fabian Nguyen et al. BIOLOGICAL CHEMISTRY
- Genomics of KPC-Producing Klebsiella pneumoniae Sequence Type 512 Clone Highlights the Role of RamR and Ribosomal S10 Protein Mutations in Conferring Tigecycline Resistance
- (2013) Laura Villa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens
- (2013) J. A. Sutcliffe et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic
- (2012) Trudy H. Grossman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The rise of the Enterococcus: beyond vancomycin resistance
- (2012) Cesar A. Arias et al. NATURE REVIEWS MICROBIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started